Costs and outcomes of colorectal cancer screening program in Isfahan, Iran

Abstract

Background Colorectal cancer is one of the most prevalent gastrointestinal cancers in Iran i.e., the fourth and the second prevalent cancer among Iranian males and females, respectively. A routine screening program is effective in the early detection of disease which can reduce the cancer burden both for individuals and society. In 2015, Iran’s Package of Essential Non- communicable Diseases program had been piloted in Shahreza city in Isfahan province. Colorectal cancer screening for the population aged 50–70 was a part of this program. So far, there was no study about the cost and outcomes of that program. Thus, this study aimed to analyze the costs and outcomes of colorectal cancer screening done from 2016 to 2019 in Shahreza. Methods This cost-outcome description study used the data of 19,392 individuals who were 50–70 years old experienced a fecal immunochemical test (FIT) and had an electronic health record. All direct costs including personnel, building space, equipment, training, etc. were extracted from the financial documents existing in the Isfahan province Health Center. The outcome was defined as positive FIT, detection of adenoma or malignancy as recorded in the E-integrated health system. Results The results of this study indicated that the direct costs of the colorectal cancer screening program during the years 2016–2019 were 7,368,707,574 Rials (321,029 PPP$) in Shahreza, Isfahan province. These costs resulted in identifying 821 people with a positive FIT test, of those 367 individuals were undergone colonoscopy. Of whom 8 cases of colorectal cancer, and 151 cases with polyps were diagnosed. Conclusion This study showed that by paying a small amount of 320 thousand international dollars we could prevent 151 cases of polyps to be progressed to colorectal cancer,resulting in a significant reduction in colorectal cancer incidence.

The diagnostic potential of miR-196a-1 in colorectal cancer

“…Annually, more than one million individuals are diagnosed with this disease [ 2 ]. In Iran, CRC is the second most common cancer in women after breast cancer and the fourth most common cancer after stomach, bladder, and prostate cancers in men [ 3 ]. Unfortunately, During the last 25 years, there has been a noticeable rise in CRC prevalence, especially among younger age groups [ 4 ].…”

Design and evaluation of a colon cancer mobile application

“…In 2020, there were approximately 1.9 million new cases of CRC, which accounted for 935,000 deaths [ 2 ]. In Iran, CRC is the fourth most common cancer after stomach, prostate, and lung cancer among men, and among women, it ranks second after breast cancer [ 3 ]. The development of CRC results from changes in the healthy epithelium of the colon, including the development of adenomatous polyps that may proliferate, grow, and accumulate genetic and epigenetic mutations over time [ 4 ].…”